Serum ca19-9 in cervical adenocarcinomas process: submission:10/07/2021 acceptance:07/31/2022 cytology high-risk human papillomavirus testing and serum ca19-9 in large cohort of patients with invasive cervical adenocarcinomas: correlation with new pathogenetic

HIGHLIGHTS

• who: Asian Pac J Cancer and colleagues from the Demographics The Institutional Review Board of Women's Hospital, School of Medicine, Zhejiang University approved this study (IRB:, ), and granted an exemption from requiring written informed consent owing to minimal risk for patient privacy exposure, healthy and other potential harms in the retrospective studyA total of , adenocarcinomas, accounting for, .7% (209/1792) of all cervical carcinomas, were searched by computer (PACS system) from the archives of the Department of Surgical Pathology, Women's Hospital, School of Medicine, Zhejiang University, China, between January , and June, . The clinical data, including . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.